Literature DB >> 19948838

Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype.

Catherine Hyams1, Jose Yuste, Katie Bax, Emilie Camberlein, Jeffrey N Weiser, Jeremy S Brown.   

Abstract

Streptococcus pneumoniae strains vary considerably in the ability to cause invasive disease in humans, and this is partially associated with the capsular serotype. The S. pneumoniae capsule inhibits complement- and phagocyte-mediated immunity, and differences between serotypes in these effects on host immunity may cause some of the variation in virulence between strains. However, the considerable genetic differences between S. pneumoniae strains independent of the capsular serotype prevent an unambiguous assessment of the effects of the capsular serotype on immunity using clinical isolates. We have therefore used capsular serotype-switched TIGR4 mutant strains to investigate the effects of the capsular serotype on S. pneumoniae interactions with complement. Flow cytometry assays demonstrated large differences in C3b/iC3b deposition on opaque-phase variants of TIGR4(-)+4, +6A, +7F, and +23F strains even though the thicknesses of the capsule layers were similar. There was increased C3b/iC3b deposition on TIGR4(-)+6A and +23F strains compared to +7F and +4 strains, and these differences persisted even in serum depleted of immunoglobulin G. Neutrophil phagocytosis of the TIGR4(-)+6A and +23F strains was also increased, but only in the presence of complement, showing that the effects of the capsular serotype on C3b/iC3b deposition are functionally significant. In addition, the virulence of the TIGR4(-)+6A and +23F strains was reduced in a mouse model of sepsis. These data demonstrate that resistance to complement-mediated immunity can vary with the capsular serotype independently of antibody and of other genetic differences between strains. This might be one mechanism by which the capsular serotype can affect the relative invasiveness of different S. pneumoniae strains.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948838      PMCID: PMC2812205          DOI: 10.1128/IAI.01056-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Comparative genomic analyses of seventeen Streptococcus pneumoniae strains: insights into the pneumococcal supragenome.

Authors:  N Luisa Hiller; Benjamin Janto; Justin S Hogg; Robert Boissy; Susan Yu; Evan Powell; Randy Keefe; Nathan E Ehrlich; Kai Shen; Jay Hayes; Karen Barbadora; William Klimke; Dmitry Dernovoy; Tatiana Tatusova; Julian Parkhill; Stephen D Bentley; J Christopher Post; Garth D Ehrlich; Fen Z Hu
Journal:  J Bacteriol       Date:  2007-08-03       Impact factor: 3.490

2.  Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae.

Authors:  J O Kim; J N Weiser
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells.

Authors:  Sven Hammerschmidt; Sonja Wolff; Andreas Hocke; Simone Rosseau; Ellruth Müller; Manfred Rohde
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.

Authors:  Aaron L Nelson; Aoife M Roche; Jane M Gould; Kannie Chim; Adam J Ratner; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

5.  Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease.

Authors:  Göran Jönsson; Lennart Truedsson; Gunnar Sturfelt; Vivi-Anne Oxelius; Jean Henrik Braconier; Anders G Sjöholm
Journal:  Medicine (Baltimore)       Date:  2005-01       Impact factor: 1.889

6.  The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms.

Authors:  Catherine Hyams; Emilie Camberlein; Jonathan M Cohen; Katie Bax; Jeremy S Brown
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

Review 7.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

8.  Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae.

Authors:  J O Kim; S Romero-Steiner; U B Sørensen; J Blom; M Carvalho; S Barnard; G Carlone; J N Weiser
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

9.  Pneumococcal capsular polysaccharide structure predicts serotype prevalence.

Authors:  Daniel M Weinberger; Krzysztof Trzciński; Ying-Jie Lu; Debby Bogaert; Aaron Brandes; James Galagan; Porter W Anderson; Richard Malley; Marc Lipsitch
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

10.  The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles.

Authors:  Mohamed Arredouani; Zhiping Yang; YaoYu Ning; Guozhong Qin; Raija Soininen; Karl Tryggvason; Lester Kobzik
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more
  51 in total

Review 1.  Pneumococci: immunology of the innate host response.

Authors:  Gavin K Paterson; Carlos J Orihuela
Journal:  Respirology       Date:  2010-07-20       Impact factor: 6.424

2.  Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation.

Authors:  Allison M Brady; Juan J Calix; Jigui Yu; Kimball Aaron Geno; Gary R Cutter; Moon H Nahm
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

3.  The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.

Authors:  Brady L Spencer; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 4.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

5.  Deletion of arcD in Streptococcus pneumoniae D39 impairs its capsule and attenuates virulence.

Authors:  Radha Gupta; Jun Yang; Yimin Dong; Edwin Swiatlo; Jing-Ren Zhang; Dennis W Metzger; Guangchun Bai
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

Review 6.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

7.  Infection with conditionally virulent Streptococcus pneumoniae Δpab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains.

Authors:  Suneeta Chimalapati; Jonathan Cohen; Emilie Camberlein; Claire Durmort; Helen Baxendale; Corné de Vogel; Alex van Belkum; Jeremy S Brown
Journal:  Infect Immun       Date:  2011-09-26       Impact factor: 3.441

8.  SssP1, a Streptococcus suis Fimbria-Like Protein Transported by the SecY2/A2 System, Contributes to Bacterial Virulence.

Authors:  Yue Zhang; Pengpeng Lu; Zihao Pan; Yinchu Zhu; Jiale Ma; Xiaojun Zhong; Wenyang Dong; Chengping Lu; Huochun Yao
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

9.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

10.  Within-host competition drives selection for the capsule virulence determinant of Streptococcus pneumoniae.

Authors:  Elena S Lysenko; Rebeccah S Lijek; Sam P Brown; Jeffrey N Weiser
Journal:  Curr Biol       Date:  2010-06-17       Impact factor: 10.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.